Small-molecule nox inhibitors: ROS-generating NADPH oxidases as therapeutic targets

Antioxidants and Redox Signaling

Volumn 11, Issue 10, 2009, Pages 2535-2552

  Jaquet, Vincent ^a   Scapozza, Leonardo ^a   Clark, Robert A ^b   Krause, Karl Heinz ^a   Lambeth, J David ^c  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PYRONE DERIVATIVE; 6,8 DIALLYL 5,7 DIHYDROXY 2 (2 ALLYL 3 HYDROXY 4 METHOXYPHENYL) 1 H BENZO(B)PYRAN 4 ONE; ABRUQUINONE A; APOCYNIN; ARSENOSOBENZENE; DIPHENYLIODONIUM SALT; ENZYME INHIBITOR; FLAVINE ADENINE NUCLEOTIDE; GLIOTOXIN; GOMISIN; HONOKIOL; INDOLE DERIVATIVE; LATAMOXEF; MAGNOLOL; N (1 CYCLOHEXYLETHYL) 4 PHENYLPHTHALAZIN 1 AMINE; NEOPTERIN; NORATHYRIOL; PERHEXILINE; PHTHALAZINE DERIVATIVE; PRODIGIOSIN; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE INHIBITOR; S 17834; THIOL DERIVATIVE; UNCLASSIFIED DRUG; VAS 2870; VAS2870; XANTHINE OXIDASE;

ANEURYSM; ARTHRITIS; ATHEROSCLEROSIS; BIOAVAILABILITY; BLOOD PRESSURE REGULATION; CHEMICAL STRUCTURE; CYTOTOXICITY; DIABETIC NEPHROPATHY; ELECTRON SPIN RESONANCE; ELECTRON TRANSPORT; ENZYME ACTIVITY; ENZYME SPECIFICITY; HEART VENTRICLE HYPERTROPHY; HEMORRHAGIC SHOCK; HUMAN; IC 50; IN VITRO STUDY; IN VIVO CULTURE; LIVER INJURY; LIVER ISCHEMIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE DEGENERATION; NONHUMAN; OTOLITH; OXIDATIVE STRESS; PAW EDEMA; PNEUMONIA; PRIORITY JOURNAL; RETINA VASCULITIS; REVIEW; STROKE; STRUCTURE ACTIVITY RELATION;

DRUG DESIGN; DRUG INDUSTRY; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MOLECULAR STRUCTURE; NADPH OXIDASE; PROTEIN SUBUNITS; REACTIVE OXYGEN SPECIES; RESPIRATORY BURST;

EID: 67651156448     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2585     Document Type: Review

References (124)

1. Abdelrahman M, Mazzon E, Bauer M, Bauer I, Delbosc S, Cristal JP, Patel NS, Cuzzocrea S, and Thiemermann C. Inhibitors of NADPH oxidase reduce the organ injury in hemorrhagic shock. Shock 23: 107-114, 2005. (Pubitemid 40222945)
2. Ai J, Wang X, and Nielsen M. Honokiol and magnolol selectively interact with GABAA receptor subtypes in vitro. Pharmacology 63: 34-41, 2001. (Pubitemid 32623459)
3. Akard LP, English D, and Gabig TG. Rapid deactivation of NADPH oxidase in neutrophils: continuous replacement by newly activated enzyme sustains the respiratory burst. Blood 72: 322-327,1988. (Pubitemid 18209323)
4. Al-Shabrawey M, Rojas M, Sanders T, Behzadian A, El-Remessy A, Bartoli M, Parpia AK, Liou G, and Caldwell RB. Role of NADPH oxidase in retinal vascular inflammation. Invest Ophthalmol Vis Sci 49: 3239-3244, 2008.
5. Aldieri E, Riganti C, Polimeni M, Gazzano E, Lussiana C, Campia I, and Ghigo D. Classical inhibitors of NOX NAD(P)H oxidases are not specific. Curr Drug Metab 9: 686-696, 2008.
6. Alvarez MC, Caldiz C, Fantinelli JC, Garciarena CD, Console GM, Chiappe de Cingolani GE, and Mosca SM. Is cardiac hypertrophy in spontaneously hypertensive rats the cause or the consequence of oxidative stress? Hypertens Res 31: 1465-1476, 2008.
7. Atkins WM. Current views on the fundamental mechanisms of cytochrome P450 allosterism. Expert Opin Drug Metab Toxicol 2: 573-579, 2006.
8. Barbieri SS, Cavalca V, Eligini S, Brambilla M, Caiani A, Tremoli E, and Colli S. Apocynin prevents cyclooxygenase 2 expression in human monocytes through NADPH oxidase and glutathione redox-dependent mechanisms. Free Radic Biol Med 37: 156-165, 2004. (Pubitemid 38760252)
9. Bayraktutan U, Draper N, Lang D, and Shah AM. Expression of functional neutrophil-type NADPH oxidase in cultured rat coronary microvascular endothelial cells. Cardiovasc Res 38: 256-262,1998. (Pubitemid 28275637)
10. Bedard K and Krause KH. The NOX family of ROSgenerating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313, 2007. (Pubitemid 46209993)
11. Berdowska A and Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. J Clin Pharm Ther 26:319-329,2001.
12. Block ML, Zecca L, and Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57-69, 2007. (Pubitemid 46011999)
13. Carmona-Cuenca I, Roncero C, Sancho P, Caja L, Fausto N, Fernandez M, and Fabregat I. Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. J Hepatol 49: 965-976, 2008.
14. Cattley RC and Glover SE. Elevated 8-hydroxydeoxyguanosine in hepatic DNA of rats following exposure to peroxisome proliferators: relationship to carcinogenesis and nuclear localization. Carcinogenesis 14: 2495-2499,1993. (Pubitemid 24016584)
15. Cayatte AJ, Rupin A, Oliver-Krasinski J, Maitland K, Sansilvestri-Morel P, Boussard MF, Wierzbicki M, Verbeuren TJ, and Cohen RA. S17834, a new inhibitor of cell adhesion and atherosclerosis that targets NADPH oxidase. Arterioscler Thromb Vase Biol 21: 1577-1584, 2001. (Pubitemid 34215575)
16. Chen JH, Wu CC, Hsiao G, and Yen MH. Magnolol induces apoptosis in vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol 368: 127-133, 2003. (Pubitemid 37041305)
17. Chen W, Pendyala S, Natarajan V, Garcia JG, and Jacobson JR. Endothelial cell barrier protection by simvastatin: GTPase regulation and NADPH oxidase inhibition. Am J Physiol Lung Cell Mol Physiol 295: L575-L583, 2008.
18. Comera C, Andre K, Laffitte J, Collet X, Galtier P, and Maridonneau-Parini I. Gliotoxin from Aspergillus fumigatus affects phagocytosis and the organization of the actin cytoskeleton by distinct signalling pathways in human neutrophils. Microbes Infect 9: 47-54, 2007. (Pubitemid 46157195)
19. Cooper JM, Petty RK, Hayes DJ, Morgan-Hughes JA, and Clark JB. Chronic administration of the oral hypoglycaemic agent diphenyleneiodonium to rats: an animal model of impaired oxidative phosphorylation (mitochondrial myopathy). Biochem Pharmacol 37: 687-694,1988.
20. Cross AR. Inhibitors of the leukocyte superoxide generating oxidase: mechanisms of action and methods for their elucidation. Free Radic Biol Med 8: 71-93,1990. (Pubitemid 20074050)
21. Cross AR and Jones OT. The effect of the inhibitor diphenylene iodonium on the superoxide-generating system of neutrophils: specific labelling of a component polypeptide of the oxidase. Biochem J 237: 111-1116,1986.
22. Cross AR and Segal AW. The NADPH oxidase of professional phagocytes: prototype of the NOX electron transport chain systems. Biochim Biophys Acta 1657: 1-22, 2004.
23. Dagher MC and Pick E. Opening the black box: lessons from cell-free systems on the phagocyte NADPH-oxidase. Biochimie 89: 1123-1132, 2007. (Pubitemid 47248685)
24. Decoursey TE and Ligeti E. Regulation and termination of NADPH oxidase activity. Cell Mol Life Sd 62:2173-2193,2005. (Pubitemid 41500537)
25. 2 generator in thyroid plasma membrane: inhibition by diphenyleneiodonium. Biochem J 301: 75-81,1994.
26. Diatchuk V, Lotan O, Koshkin V, Wikstroem P, and Pick E. Inhibition of NADPH oxidase activation by 4-(2aminoethyl)-benzenesulfonyl fluoride and related compounds. J Biol Chem 272: 13292-13301,1997. (Pubitemid 27216760)
27. Dikalov S, Griendling KK, and Harrison DG. Measurement of reactive oxygen species in cardiovascular studies. Hypertension 49: 717-727, 2007. (Pubitemid 351688335)
28. Doussiere J, Gaillard J, and Vignais PV. The heme component of the neutrophil NADPH oxidase complex is a target for aryliodonium compounds. Biochemistry 38: 3694-3703,1999. (Pubitemid 129514625)
29. Doussiere J, Poinas A, Blais C, and Vignais PV. Phenylarsine oxide as an inhibitor of the activation of the neutrophil NADPH oxidase: identification of the beta subunit of the flavocytochrome b component of the NADPH oxidase as a target site for phenylarsine oxide by photoaffinity labeling and photoinactivation. Eur J Biochem 251: 649-658, 1998. (Pubitemid 28108958)
30. Ellis JA, Cross AR, and Jones OT. Studies on the electrontransfer mechanism of the human neutrophil NADPH oxidase. Biochem J 262: 575-579,1989. (Pubitemid 19228139)
31. Ellis JA, Mayer SJ, and Jones OT. The effect of the NADPH oxidase inhibitor diphenyleneiodonium on aerobic and anaerobic microbicidal activities of human neutrophils. Biochem J 251: 887-891,1988.
32. Fiander H and Schneider H. Compounds that induce isoforms of glutathione S-transferase with properties of a critical enzyme in defense against oxidative stress. Biochem Biophys Res Commun 262: 591-595,1999. (Pubitemid 29443701)
33. Gatley SJ and Martin JL. Some aspects of the pharmacology of diphenyleneiodonium, a bivalent iodine compound. Xenobiotica 9: 539-546,1979.
34. Glen RC and Adams SE. Similarity metrics and descriptor spaces: which combinations to choose? QSAR Comb Sci 25: 1133-1142, 2006.
35. Goldberg B and Stern A. The role of the superoxide anion as a toxic species in the erythrocyte. Arch Biochem Biophys 178: 218-225, 1977. (Pubitemid 8035435)
36. Gupte SA. Glucose-6-phosphate dehydrogenase: a novel therapeutic target in cardiovascular diseases. Curr Opin Invest Drugs 9: 993-1000, 2008.
37. Gupte SA, Kaminski PM, Floyd B, Agarwal R, Ali N, Ahmad M, Edwards J, and Wolin MS. Cytosolic NADPH may regulate differences in basal Nox oxidase-derived superoxide generation in bovine coronary and pulmonary arteries. Am J Physiol Heart Circ Physiol 288: H13-H21,2005. (Pubitemid 40023822)
38. Hancock JT and Jones OT. The inhibition by diphenyleneiodonium and its analogues of superoxide generation by macrophages. Biochem J 242: 103-107, 1987.
39. Harraz MM, Marden JJ, Zhou W, Zhang Y, Williams A, Sharov VS, Nelson K, Luo M, Paulson H, Schoneich C, and Engelhardt JF. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J Clin Invest 118: 659-670, 2008. (Pubitemid 351206555)
40. Heumuller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schroder K, and Brandes RP. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 51: 211-217, 2008. (Pubitemid 351159930)
41. Holland JA, O'Donnell RW, Chang MM, Johnson DK, and Ziegler LM. Endothellal cell oxidant production: effect of NADPH oxidase inhibitors. Endothelium 7: 109-119, 2000.
42. Holland PC, Clark MG, Bloxham DP, and Lardy HA. Mechanism of action of the hypoglycemic agent diphenyleneiodonium. J Biol Chem 248: 6050-6056,1973.
43. Hsu MF, Raung SL, Tsao LT, Kuo SC, and Wang JP. Cellular localization of the inhibitory action of abruquinone A against respiratory burst in rat neutrophils. Br J Pharmacol 120: 917-925, 1997
44. Hsu MF, Raung SL, Tsao LT, Lin CN, and Wang JP. Examination of the inhibitory effect of norathyriol in formylmethionyl-leucyl-phenylalanineinduced respiratory burst in rat neutrophils. Free Radic Biol Med 23:1035-1045,1997. (Pubitemid 27451291)
45. Hwang TL, Yeh SH, Leu YL, Chern CY, and Hsu HC. Inhibition of superoxide anion and elastase release in human neutrophils by 3'-isopropoxychalcone via a cAMPdependent pathway. Br J Pharmacol 148: 78-87, 2006. (Pubitemid 43675603)
46. Ikai T, Akao Y, Nakagawa Y, Ohguchi K, Sakai Y, and Nozawa Y. Magnolol-induced apoptosis is mediated via the intrinsic pathway with release of AIF from mitochondria in U937 cells. Biol Pharm Bull 29: 2498-2501, 2006. (Pubitemid 44885876)
47. Johnson DK, Schillinger KJ, Kwait DM, Hughes CV, McNamara EJ, Ishmael F, O'Donnell RW, Chang MM, Hogg MG, Dordick JS, Santhanam L, Ziegler LM, and Holland JA. Inhibition of NADPH oxidase activation in endothelial cells by ortho-methoxy-substituted catechols. Endothelium 9: 191-203, 2002. (Pubitemid 35021589)
48. Kalinowski L, Dobrucki IT, and Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circuktion 109: 2511-2517, 2004. (Pubitemid 38720549)
49. Kennedy JA, Beck-Oldach K, McFadden-Lewis K, Murphy GA, Wong YW, Zhang Y, and Horowitz JD. Effect of the anti-anginal agent, perhexiline, on neutrophil, valvular and vascular superoxide formation. Eur J Pharmacol 531:13-19, 2006. (Pubitemid 43202209)
50. Kim DE, Suh YS, Lee MS, Kim KY, Lee JH, Lee HS, Hong KW, and Kim CD. Vascular NAD(P)H oxidase triggers delayed cerebral vasospasm after subarachnoid hemorrhage in rats. Stroke 33: 2687-2691, 2002.
51. Kiss PJ, Knisz J, Zhang Y, Baltrusaitis J, Sigmund CD, Thalmann R, Smith RJ, Verpy E, and Banfi B. Inactivation of NADPH oxidase organizer 1 results in severe imbalance. Curr Biol 16: 208-213, 2006. (Pubitemid 43117437)
52. Kojima S, Nomura T, Icho T, Kajiwara Y, Kitabatake K, and Kubota K. Inhibitory effect of neopterin on NADPHdependent superoxide-generating oxidase of rat peritoneal macrophages. FEBS Lett 329: 125-128,1993. (Pubitemid 23248263)
53. Kono H, Rusyn I, Uesugi T, Yamashina S, Connor HD, Dikalova A, Mason RP, and Thurman RG. Diphenyleneiodonium sulfate, an NADPH oxidase inhibitor, prevents early alcohol-induced liver injury in the rat. Am J Physiol Gastrointest Liver Physiol 280: G1005-G1012, 2001. (Pubitemid 32436039)
54. Krotz F, Keller M, Derflinger S, Schmid H, Gloe T, Bassermann F, Duyster J, Cohen CD, Schuhmann C, Klauss V, Pohl U, Stempfle HU, and Sohn HY. Mycophenolate acid inhibits endothelial NAD(P)H oxidase activity and superoxide formation by a Racl-dependent mechanism. Hypertension 49: 201-208, 2007. (Pubitemid 46360361)
55. Kume A and Dinauer MC. Gene therapy for chronic granulomatous disease. J Lab Clin Med 135: 122-128, 2000. (Pubitemid 30105070)
56. Kutsumi H, Kawai K, Johnston RB Jr, and Rokutan K. Evidence for participation of vicinal dithiols in the activation sequence of the respiratory burst of human neutrophils. Blood 85: 2559-2569, 1995.
57. Lacy F, O'Connor DT, and Schmid-Schonbein GW. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens 16: 291-303, 1998. (Pubitemid 28101757)
58. ++, and protein kinase C. J Bioenerg Biomembr 20: 709-733,1988.
59. Lambeth JD, Krause KH, and Clark RA. NOX enzymes as novel targets for drug development. Semj'n Immunopathol 30: 339-363, 2008.
60. Lange S, Heger J, Euler G, Wartenberg M, Piper HM, and Sauer H. Platelet-derived growth factor BB stimulates vasculogenesis of embryonic stem cell-derived endothelial cells by calcium-mediated generation of reactive oxygen species. Cardiovasc Res 81: 159-168, 2009.
61. Lassegue B and Griendling KK. Mycophenolic acid is a new Nox2 inhibitor. Hypertension 49: 25-26, 2007. (Pubitemid 46360336)
62. Lassegue B, Sorescu D, Szocs K, Yin Q, Akers M, Zhang Y, Grant SL, Lambeth JD, and Griendling KK. Novel gp91(phox) homologues in vascular smooth muscle cells: noxl mediates angiotensin Il-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 88: 888-894, 2001. (Pubitemid 32441466)
63. Le Cabec V and Maridonneau-Parini I. Complete and reversible inhibition of NADPH oxidase in human neutrophils by phenylarsine oxide at a step distal to membrane translocation of the enzyme subunits. J Biol Chem 270:2067-2073,1995.
64. Li G, Cui G, Tzeng NS, Wei SJ, Wang T, Block ML, and Hong JS. Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage. FASEB J 19: 489-1196, 2005. (Pubitemid 40471239)
65. Liou KT, Shen YC, Chen CF, Tsao CM, and Tsai SK. The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species production. Eur J Pharmacol 475: 19-27, 2003.
66. Liou KT, Shen YC, Chen CF, Tsao CM, and Tsai SK. Honokiol protects rat brain from focal cerebral ischemia-reperfusion injury by inhibiting neutrophil infiltration and reactive oxygen species production. Brain Res 992:159-166,2003.
67. Liu PG, He SQ, Zhang YH, and Wu J. Protective effects of apocynin and allopurinol on ischemia/reperfusion-induced liver injury in mice. World J Gastroenterol 14: 2832-2837, 2008.
68. Miesel R, Kurpisz M, and Kroger H. Suppression of inflammatory arthritis by simultaneous inhibition of nitric oxide synthase and NADPH oxidase. Free Radic Biol Med 20: 75-81,1996. (Pubitemid 26018505)
69. Mitsuyama T, Takeshige K, and Minakami S. Cyclic AMP inhibits the respiratory burst of electropermeabilized human neutrophils at a downstream site of protein kinase C. Biochim Biophys Acta 1177: 167-173,1993. (Pubitemid 23169571)
70. Moulton P, Martin H, Ainger A, Cross A, Hoare C, Doel J, Harrison R, Eisenthal R, and Hancock J. The inhibition of flavoproteins by phenoxaiodonium, a new iodonium analogue. Eur J Pharmacol 401: 115-120, 2000. (Pubitemid 30488185)
71. Nakagami H, Kaneda Y, Ogihara T, and Morishita R. Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. Curr Diabetes Rev 1: 59-63, 2005.
72. Nakano Y, Longo-Guess CM, Bergstrom DE, Nauseef WM, Jones SM, and Banfi B. Mutation of the Cyba gene encoding p22phox causes vestibular and immune defects in mice. J Clin Invest 118: 1176-1185, 2008.
73. Nakashima T, Iwashita T, Fujita T, Sato E, Niwano Y, Kohno M, Kuwahara S, Harada N, Takeshita S, and Oda T. A prodigiosin analogue inactivates NADPH oxidase in macrophage cells by inhibiting assembly of p47phox and Rac. J Biochem 143:107-115, 2008. (Pubitemid 351197716)
74. Nikolova N and Jaworska J. Approaches to measure chemical similarity: a review. QSAR Comb Sci 22:1006-1026,2003. (Pubitemid 38200482)
75. Nishida S, Yoshida LS, Shimoyama T, Nunoi H, Kobayashi T, and Tsunawaki S. Fungal metabolite gliotoxin targets flavocytochrome b558 in the activation of the human neutrophil NADPH oxidase. Infect Immun 73: 235-244, 2005. (Pubitemid 40041114)
76. O'Donnell BV, Tew DG, Jones OT, and England PJ. Studies on the inhibitory mechanism of iodonium compounds with special reference to neutrophil NADPH oxidase. Biochem J 290: 41-119,1993.
77. O'Donnell VB, Smith GC, and Jones OT. Involvement of phenyl radicals in iodonium inhibition of flavoenzymes. Mol Pharmacol 46: 778-785, 1994. (Pubitemid 24984459)
78. Oelze M, Daiber A, Brandes RP, Hortmann M, Wenzel P, Hink U, Schulz E, Mollnau H, von Sandersleben A, Kleschyov AL, Mulsch A, Li H, Forstermann U, and Munzel T. Nebivolol inhibits superoxide formation by NADPH oxi- dase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 48: 677-684, 2006. (Pubitemid 44843872)
79. Paffenholz R, Bergstrom RA, Pasutto F, Wabnitz P, Munroe RJ, Jagla W, Heinzmann U, Marquardt A, Bareiss A, Laufs J, Russ A, Stumm G, Schimenti JC, and Bergstrom DE. Vestibular defects in head-tilt mice result from mutations in Nox3, encoding an NADPH oxidase. Genes Dev 18: 486-491,2004. (Pubitemid 38372805)
80. Pagano PJ, Ito Y, Tornheim K, Gallop PM, Tauber AI, and Cohen RA. An NADPH oxidase superoxide-generating system in the rabbit aorta. Am J Physiol 268: H2274-H2280,1995.
81. Page P, Orchard M, Fioraso-Cartier L, and Mottironi B. Pyrazolo pyridine derivatives as NADPH oxidase inhibitors, WO 2008/113856 A1. Genkyotex (CH) 2008.
82. Page P, Orchard M, Fioraso-Cartier L, and Mottironi B. Tetrahydroindole derivatives as NADPH oxidase inhibitors, WO 2008/116926 Al. Genkyotex (CH) 2008.
83. Pandey R, Chander R, and Sainis KB. Prodigiosins: a novel family of immunosuppressants with anti-cancer activity. Indian J Biochem Biophys 44: 295-302, 2007.
84. Peters EA, Hiltermann JT, and Stalk J. Effect of apocynin on ozone-induced airway hyperresponsiveness to methacholine in asthmatics. Free Radic Biol Med 31:1442-1447, 2001.
85. Pinto MM, Sousa ME, and Nascimento MS. Xanthone derivatives: new insights in biological activities. Curr Med Chem 12: 2517-2538, 2005. (Pubitemid 41408417)
86. Poinas A, Gaillard J, Vignais P, and Doussiere J. Exploration of the diaphorase activity of neutrophil NADPH oxidase. Eur J Biochem 269:1243-1252, 2002.
87. Puddu P, Puddu GM, Cravero E, Rosati M, and Muscari A. The molecular sources of reactive oxygen species in hypertension. Blood Press 17: 70-77, 2008. (Pubitemid 351891172)
88. Riganti C, Costamagna C, Doublier S, Miraglia E, Polimeni M, Bosia A, and Ghigo D. The NADPH oxidase inhibitor apocynin induces nitric oxide synthesis via oxidative stress. Toxicol Appl Pharmacol 228: 277-285, 2008.
89. Rinaldi M, Moroni P, Paape MJ, and Bannerman DD. Evaluation of assays for the measurement of bovine neutrophil reactive oxygen species. Vet Immunol Immunopathol 115: 107-125, 2007. (Pubitemid 44908672)
90. Roussin A, Le Cabec V, Lonchampt M, De Nadai J, Canet E, and Maridonneau-Parini I. Neutrophil-associated inflammatory responses in rats are inhibited by phenylarsine oxide. Eur J Pharmacol 322: 91-96, 1997. (Pubitemid 27117929)
91. Schappi MG, Jaquet V, Belli DC, and Krause KH. Hyperinflammation in chronic granulomatous disease and antiinflammatory role of the phagocyte NADPH oxidase. Semj'n Immunopathol 30: 255-271, 2008.
92. Selemidis S, Sobey CG, Wingler K, Schmidt HH, and Drummond GR. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 120: 254-291, 2008.
93. Seno K, Nishi K, Matsuo Y, and Fujishita T. Pyrazolo [1,5-A] pyrimidine derivative and NAD(P)H oxidase inhibitor containing the same, US 2006/0089362. Osaka, Japan: Shionogi & Co., Ltd., 2006.
94. Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Piastre O, Sienkiewicz A, Forro L, Schlegel W, and Krause KH. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J 406:105-114,2007. (Pubitemid 47264740)
95. Serrander L, Jaquet V, Bedard K, Piastre O, Hartley O, Arnaudeau S, Demaurex N, Schlegel W, and Krause KH. NOX5 is expressed at the plasma membrane and generates superoxide in response to protein kinase C activation. Biochimie 89: 1159-1167, 2007. (Pubitemid 47248008)
96. Sheu ML, Chiang CK, Tsai KS, Ho FM, Weng TI, Wu HY, and Liu SH. Inhibition of NADPH oxidase-related oxidative stress-triggered signaling by honokiol suppresses high glucose-induced human endothelial cell apoptosis. Free Radic Biol Med 44: 2043-2050, 2008.
97. Stefanska J and Pawliczak R. Apocynin: molecular aptitudes. Medktors Inflamm 2008: 106507, 2008.
98. Stielow C, Catar RA, Muller G, Wingler K, Scheurer P, Schmidt HH, and Morawietz H. Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells. Biochem Biophys Res Commun 344: 200-205, 2006.
99. Stolk J, Hiltermann TJ, Dijkman JH, and Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol 11: 95-102,1994.
100. Stuehr DJ, Fasehun OA, Kwon NS, Gross SS, Gonzalez JA, Levi R, and Nathan CF. Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs. FASEB J 5: 98-103,1991. (Pubitemid 21892842)
101. Tang XN, Cairns B, Cairns N, and Yenari MA. Apocynin improves outcome in experimental stroke with a narrow dose range. Neuroscience 154: 556-562, 2008.
102. Tanito M, Agbaga MP, and Anderson RE. Upregulation of thioredoxin system via Nrf2-antioxidant responsive element pathway in adaptive-retinal neuroprotection in vivo and in vitro. Free Radic Biol Med 42: 1838-1850, 2007.
103. ten Freyhaus H, Huntgeburth M, Wingler K, Schnitker J, Baumer AT, Vantler M, Bekhite MM, Wartenberg M, Sauer H, and Rosenkranz S. Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell Chemotaxis, but not proliferation. Cardiovasc Res 71: 331-341, 2006.
104. Touyz RM. Apocynin, NADPH oxidase, and vascular cells: a complex matter. Hypertension 51:172-174, 2008.
105. Tsai SK, Huang SS, and Hong CY. Myocardial protective effect of honokiol: an active component in Magnolk officinalis. Planta Med 62: 503-506, 1996.
106. Tsunawaki S, Yoshida LS, Nishida S, Kobayashi T, and Shimoyama T. Fungal metabolite gliotoxin inhibits assembly of the human respiratory burst NADPH oxidase. Infect Immun 71: 3373-3382, 2004. (Pubitemid 38697762)
107. Van den Worm E, Beukelman CJ, Van den Berg AJ, Kroes BH, Labadie RP, and Van Dijk H. Effects of methoxylation of apocynin and analogs on the inhibition of reactive oxygen species production by stimulated human neutrophils. Eur J Pharmacol 433: 225-230, 2001. (Pubitemid 34045183)
108. Vejrazka M, Micek R, and Stipek S. Apocynin inhibits NADPH oxidase in phagocytes but stimulates ROS production in non-phagocytic cells. Biochim Biophys Acta 1722: 143-147, 2005. (Pubitemid 40299004)
109. 2 in phagocyte-induced hypermetabolism and pulmonary injury. J Appl Physiol 78: 112-116,1995.
110. Wang JP, Chang LC, Hsu MF, and Lin CN. The blockade of formyl peptide-induced respiratory burst by 2',5'dihydroxy-2-furfurykhalcone involves phospholipase D signaling in neutrophils. Naunyn Schmiedebergs Arch Pharmacol 368: 166-174, 2003.
111. Wang JP, Hsu MF, Raung SL, Chang LC, Tsao LT, Lin PL, and Chen CC. Inhibition by magnolol of formy lmethionylleucyl-phenyl alanine-induced respiratory burst in rat neutrophils. J Pharm Pharmacol 51: 285-294,1999.
112. Wang JP, Raung SL, Hsu MF, and Chen CC. Inhibition by gomisin C (a lignan from Schizandra chinensis) of the respiratory burst of rat neutrophils. Br J Pharmacol 113: 945-953,1994.
113. Wang JP, Raung SL, Kuo YH, and Teng CM. Daphnoretininduced respiratory burst in rat neutrophils is, probably, mainly through protein kinase C activation. Eur J Pharmacol 288: 341-348,1995.
114. Wang JP, Raung SL, Tsao LT, and Lin CN. Evidence for the involvement of protein kinase C inhibition by norathyriol in the reduction of phorbol ester-induced neutrophil superoxide anion generation and aggregation. Eur J Pharmacol 336: 81-88,1997.
115. Wang JP, Tsao LT, Raung SL, and Lin CN. Investigation of the inhibitory effect of broussochalcone A on respiratory burst in neutrophils. Eur J Pharmacol 320: 201-208,1997. (Pubitemid 27076747)
116. Wang Q, Smith RE, Luchtefeld R, Sun AY, Simonyi A, Luo R, and Sun GY. Bioavailability of apocynin through its conversion to glycoconjugate but not to diapocynin. Phytomedicine 15: 496-503, 2008. (Pubitemid 351790760)
117. Williams HC and Griendling KK. NADPH oxidase inhibitors: new antihypertensive agents? J Cardiovasc Pharmacol 50: 9-16, 2007. (Pubitemid 47220441)
118. Yagi K. Simple procedure for specific assay of lipid hydroperoxides in serum or plasma. Methods Mol Biol 108: 107-110, 1998.
119. Yamamoto E, Tamamaki N, Nakamura T, Kataoka K, Tokutomi Y, Dong YF, Fukuda M, Matsuba S, Ogawa H, and Kim-Mitsuyama S. Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation. Stroke 39: 3049-3056, 2008.
120. Yamamoto T and Yamada K. Specific NAD(P)H oxidase inhibitor WO 2004/089412. Osaka-shi, Japan: Mitsubishi Pharma Corporation, 2006.
121. Yang S, Yang J, Yang Z, Chen P, Fraser A, Zhang W, Pang H, Gao X, Wilson B, Hong JS, and Block ML. Pituitary adenylate cyclase-activating polypeptide (PACAP) 38 and PACAP4-6 are neuroprotective through inhibition of NADPH oxidase: potent regulators of microglia-mediated oxidative stress. J Pharmacol Exp Ther 319: 595-603,2006. (Pubitemid 44776362)
122. Yoshida LS, Abe S, and Tsunawaki S. Fungal gliotoxin targets the onset of superoxide-generating NADPH oxidase of human neutrophils. Biochem Biophys Res Commun 268: 716-723, 2000 (Pubitemid 30150857)
123. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ, and Cohen RA. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Dtafeeies 55: 2180-2191, 2006. (Pubitemid 44743614)
124. Zhang W, Wang T, Qin L, Gao HM, Wilson B, Ali SF, Hong JS, and Liu B. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J 18: 589-591, 2004.